Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Healthy Volunteers
Interventions: Placebo Comparator: Cohort 1 Placebo, 52364 3 mg, Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo, 52364 10 mg, 52364 30 mg, 52364 100 mg, 52364 1 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Weight Loss
Interventions: Dapagliflozin Tablet, Placebo Tablet; Drug
Lead sponsor: Christopher Bell; Other
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Pain
Interventions: clonidine, adenosine, placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Winston-Salem, North Carolina

Conditions: Cocaine Dependence, Opioid Dependency
Interventions: levetiracetam, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Cardiovascular Diseases, Heart Diseases, Heart Failure, Congestive
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 50 Years and older
Enrollment: 3,445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 155
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 120 more

Conditions: Borderline Personality Disorder
Interventions: Rexulti, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Treprostinil Inhalation Solution, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Alcohol Dependence
Interventions: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1, Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: COVID, Corona Virus Infection, COVID19
Interventions: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo; Biological · Other
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more

Conditions: Acute Myeloid Leukemia, Adult
Interventions: Revumenib, Placebo; Drug
Lead sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland; Other
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Jacksonville, Florida + 11 more

Conditions: Bipolar Disorder
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Orange City, Florida • Fayetteville, Georgia • Smyrna, Georgia + 6 more

Conditions: Pain
Interventions: placebo, valdecoxib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 68
States / cities: Birmingham, Alabama • Northport, Alabama • Glendale, Arizona + 46 more

Conditions: Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 46
States / cities: Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more

Conditions: Gastric Adenocarcinoma
Interventions: Andecaliximab, Placebo, Leucovorin, 5-fluorouracil, Oxaliplatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 31
States / cities: La Jolla, California • Los Angeles, California • Whittier, California + 27 more

Conditions: Venous Thromboembolism
Interventions: Open-label Semuloparin sodium, Placebo (for Semuloparin sodium), Semuloparin sodium; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Post Traumatic Stress Disorder
Interventions: Intervention D SLS-002, Intervention D Placebo; Drug
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2028 – 2029
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more

Conditions: Nausea, Vomiting
Interventions: Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 21 Years to 89 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Healthy
Interventions: INX-08189 50 mg QD X 5 days, INX-08189 / Victrelis 800 mg TID X three days, Victrelis 800 mg TID x 3 days, Victrelis 800 mg TID with INX-08189 50 mg QD, Placebo with Victrelis 800 mg, Cohort 2: Victrelis 800 mg with Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Type 2 Diabetes Mellitus
Interventions: AR-C165395XX, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions: TransCon PTH, Placebo for TransCon PTH; Combination Product
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 5
States / cities: Chicago, Illinois • Rochester, Minnesota • Great Neck, New York + 2 more

Conditions: Leukemia, Myeloid, Acute
Interventions: glasdegib, daunorubicin + cytarabine, azacitidine, Placebo, cytarabine, HSCT; Drug · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 30
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 14 more

Conditions: Pelvic Organ Prolapse (POP), Postoperative Pain, Urogynecology
Interventions: Suzetrigine, Placebo; Drug
Lead sponsor: Aditi Talkad; Other
Eligibility: 40 Years to 80 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Physical Activity
Interventions: Metformin, Placebo, Carbohydrate Beverage, Protein Beverage; Drug · Dietary Supplement
Lead sponsor: Colorado State University; Other
Eligibility: 55 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Cystic Fibrosis
Interventions: Sildenafil (Acute-1 hour), Sildenafil (Subchronic-4 weeks), Placebo; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Augusta, Georgia

Search by objective public record fields.

First Safety Study in Humans of a Single Dose of CPG 52364

Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?

Clonidine Versus Adenosine to Treat Neuropathic Pain

Efficacy of Levetiracetam in Cocaine-Abusing Methadone Maintained Patients

Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function

Brexpiprazole in Borderline Personality Disorder

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse

hCT-MSCs for COVID19 ARDS

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery

Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002

The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

Suzetrigine Following Urogynecologic Surgery: Investigation of Postoperative Pain Management

Milk Protein Feeding After Aerobic Exercise in Older Adults With Pre-diabetes Taking the Biguanide Metformin

Blood Flow and Vascular Function in Cystic Fibrosis